{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103983","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.518447+00:00","generated_at":"2026-05-17T19:31:09.743895+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Revolution Medicines Q2 net loss $247.8M; advances Phase 3 RAS trials; $2B Royalty Pharma deal","bullets":["Net loss $247.8M vs $133.2M YoY; R&D expenses rose to $224.1M; FY2025 net loss guidance $1.03B-$1.09B.","FDA Breakthrough Therapy Designation for daraxonrasib (KRAS G12C PDAC) and elironrasib (KRAS G12C NSCLC).","Entered $2B flexible funding agreement with Royalty Pharma; first $250M tranche received; cash $2.1B.","RASolute 302 Phase 3 trial for PDAC enrollment to complete this year; data readout expected 2026.","Plans to initiate registrational trials for first-line PDAC and adjuvant PDAC in 2025; Phase 3 for first-line NSCLC in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103983","json":"https://secwatch.observer/filing/0000950170-25-103983.json","markdown":"https://secwatch.observer/filing/0000950170-25-103983.md","text":"https://secwatch.observer/filing/0000950170-25-103983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017025103983/0000950170-25-103983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017025103983/rvmd-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:31:09.743895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}